-
Mashup Score: 0
Findings from three randomized controlled trials suggest that treatment with the IL-6 inhibitor tocilizumab has little benefit for hospitalized patients with COVID-19.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
News: Current #ClinicalTrial evidence suggests #tocilizumab may not be beneficial for people with #COVID19. Click through to read more about the BACC Bay, RCT-TCZ-COVID-19, and CORIMUNO-19 studies @NEJM @JAMAInternalMed #IL6inhibitors https://t.co/dEEdjTxwbr